Intelligent Application of Breast Cancer Trials Data in the Clinic - European Medical Journal

Continue

Intelligent Application of Breast Cancer Trials Data in the Clinic

Oncology
Download PDF

Summary of presentations from the prIME Oncology satellite symposium held at the European Cancer Congress 2015 in Vienna, Austria, on 25th September 2015

Author: Joanne Franklin1

 

Chairperson:
Sunil Verma2
Speakers:
Sibylle Loibl,3 Pierfranco Conte,4 Peter Schmid,5 Christos Sotiriou6

1. prIME Oncology, The Hague, Netherlands 
2. Sunnybrook Health Sciences Center, Toronto, Ontario, Canada
3. University of Frankfurt, Frankfurt, Germany 
4. Ospedale Policlinico di Modena, Modena, Italy 
5. Barts Cancer Institute, London, UK 
6. Institut Jules Bordet, Brussels, Belgium

Disclosure:

Pierfranco Conte has received consulting fees from Roche and Novartis. He has also received fees for non-CME services from Novartis, Roche, AstraZeneca, and Celgene. Joanne Franklin has no relevant financial relationships to disclose. Sibylle Loibl has received consulting fees (for her institution) from Celgene and Amgen. She has also received fees (for her institution) for performing contracted research for Amgen, AstraZeneca, Celgene, Roche, and Pfizer. Peter Schmid has received consulting fees from Genentech. Christos Sotiriou has received consulting fees from Cepheid, Astellas, and Vertex Pharmaceuticals. Sunil Verma has received consulting fees from Pfizer, Novartis, Roche, Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, Eisai, and Eli Lilly.

Acknowledgements:

Editorial assistance was provided by Ms Heather Tomlinson, prIME Oncology.

Support:

This educational activity was supported by Roche and Genomic Health.

Citation:
EMJ Oncol. ;3[2]:40-48. DOI/10.33590/emjoncol/10313365. https://doi.org/10.33590/emjoncol/10313365.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

This meeting commenced with a talk from Prof Loibl on neoadjuvant and adjuvant strategies for HER2positive (human epidermal growth factor receptor 2-positive) early breast cancer (EBC), which featured a précis on the most pertinent, recent trial data and how these data may shape future treatment decisions in clinical practice. Prof Conte moved the discussion forward by addressing how recent studies may lead towards a new standard of care (SoC) and treatment paradigms in patients with metastatic breast cancer. Prof Schmid gave an overview of potential strategies that could be used to prevent or overcome endocrine therapy resistance in patients with hormone receptor-positive breast cancer. The session was concluded with a presentation on ‘Precision Medicine for Metastatic Breast Cancer’ by Prof Sotiriou, in which he highlighted the potential applications of precision medicine and some of the different approaches that have been used in metastatic breast cancer. Prof Verma, the meeting chair, opened the symposium and facilitated the discussion sessions. The contents of the presentations and discussions are summarised herein.

Please click here to see a webcast of the live meeting.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.